ClinicalTrials.gg
CompletedNCT03498833CKOAIUpdated Mar 7, 2019

Comprehensive Knee Osteoarthritis Index (CKOAI): Scale Development, Validation and Reliability Testing

An interventional study of Test-retest reliability testing in Osteo Arthritis Knee, sponsored by Maharishi Markendeswar University (Deemed to be University). Completed at 1 site in India. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-07.

Sponsored by Maharishi Markendeswar University (Deemed to be University) · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Study summary

Background:

Symptoms, balance, mobility, activities of daily life (ADL) and quality of life (QoL) are to be considered in rehabilitation of the individuals with knee osteoarthritis (IKOA). There are several scales to evaluate subjective perceptions and individual components in patients with osteoarthritis (OA). Till date, no scale is available to measure the combined balance, mobility, ADL and QoL in PKOA.

Objectives:

The objectives of the study are to develop a combined measure of symptoms, balance, mobility, ADL and QoL in PKOA, as comprehensive knee osteoarthritis index (CKOAI) and to validate the scale for its content, reliability and minimum detectable change (MDC)

Methods:

The study consists of a three stages. First stage is the scale (CKOI) item development and validation. This includes domain and item generating through systematic literature search to extract items related symptoms, balance, mobility, ADL and QoL in IKOA based on the International Classification of Functioning, Disability and Health (ICF) and through structured interviews. During scale validation, an expert panel will review the generated domains and items by Delphi Method, which will undergo revision and pilot testing. Based on the responsiveness of pilot testing will be revised finally. Second stage is to test re-test reliability. The third stage is to report the standard error of measurement (SEM) and minimal detectable change (MDC).

Data analysis:

All the domains and items in CKOAI will undergo reliability and criterion-related validity. Minimum 50 IKOA will be evaluated with the scale on two occasions within two weeks to establish test retest reliability. Cronbach's alpha for internal consistency and Intra class correlation coefficient for test retest reliability will be used to determine the degree of consistency of items in the scale. MDC will be calculated using the formulae, SEM = SD x √ (1-reliability) and MDC95 = √2 x (1.9) x (SEM). Significant level will be set at p value less than 0.05 (p \< 0.05) to minimize the type-I error.

Read the detailed description

Introduction:

One of the worldwide leading causes of disability and pain is osteoarthritis. 22% to 39% of 1.252 billion population suffer from osteoarthritis (OA). Hip and knee OA are the most prevalent forms of OA with the overall prevalence of knee OA is 28.7%. This will increase by 33.5% in 2030 due to alarming increase in aging population. Individuals with knee OA (IKOA) are seen with deficits in static and dynamic balance which comprises of impaired proprioception, muscle strength, disturbed postural control and decreased range of motion at knee joint. Furthermore, IKOA have pain and increase physical limitation and functional limitation. Eventually decreasing their quality of life (QoL).

Static balance in IKOA are assessed using several outcome measures such as, timed single-leg stance, functional reach test and variation of postural sway in unipedal or bipedal stance. More than two decade, Berg Balance Scale and Tinetti Performance-Oriented Mobility Assessment (balance subscale) were used to asses dynamic balance. Recently, Community Balance and Mobility Scale (CB\&M) have been validated for the purpose. Isokinetic dynamometer has been in use for the purpose of estimating muscle strength. Proprioception was measured by joint repositioning test. Several researchers explored QoL in IKOA,and combined with functional independence.

Various measures of knee function adopted by International Knee Documentation Committee (IKDC) are subjective in nature. Patient reported problem based rating scale in IKOA with objective scoring is still lacking. There, the purpose of this research project is to develop a rating scale which does combine assessment of balance, mobility, ADL and QoL in IKOA.

Statement of the Problem:

The existing scales could not provide comprehensive assessment for balance, mobility, ADL and QoL in IKOA. Hence, there is a need to develop an objective scale to measure the above domains in IKOA

Purpose of the study:

The purpose of the study is to develop an objective combined assessment of symptoms, balance, mobility, ADL and QoL in IKOA (CKOAI) using systematic approach.

Objectives of the study:

  1. To develop scale items and domains of CKOAI
  2. To validate the developed scale for content validity
  3. To estimate reliability of CKOAI
  4. To report SEM and MDC

Procedure:

The study will be of cross-sectional observational study of scale validation. The study protocol was approved by the Institutional Ethics Committee of Maharishi Markandeshwar (Deemed-to-be) University (MMU/IEC/1021) on 8.12.2017. The study will consists of three major phases, comprising of item and domain generation, validation, reliability testing and estimating MDC.

Phase 1: Scale Development

Sub-Phase 1:Domain and item development:

  1. Domain and item generating:

    using literature search and direct patient interviews.

    - Literature search: English language literature will be searched in databases.

    - Direct interview

  2. Grouping item in domain Sub-phase 2: Content Validation

    • Using Delphi Method Sub-phase 3: First draft and scoring criteria Sub-phase 4: Pilot test Sub-phase 5: Revision Sub-phase 6: Final draft

Phase 2: Reliability testing

  1. Check for internal consistency
  2. Intra-rater reliability
  3. Test-retest reliability

Phase 3: Estimating SEM and MDC

MDC will be calculated using the formulae, SEM = SD x √ (1-reliability) and MDC95 = √2 x (1.9) x (SEM). Significant level will be set at p≤ 0.05 to minimize the type-I error. For MCID, responsiveness of the scale will be determined on two occasions after regular conventional physiotherapy treatment of two week duration.

02

Conditions studied

  • Osteo Arthritis Knee

Browse trials for

Keywords

  • domains
  • item development
  • osteoarthritis
  • scale formulation
  • test retest reliability
03

In context

Osteoarthritis

4,445 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 52 is below the median of 70 across 3,474 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Maharishi Markendeswar University (Deemed to be University) is the lead sponsor of 41 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with osteoarthritic changes of grade 1 and greater on knee radiograph (Kellgren and Lawrence)
  • Individuals with unilateral or bilateral knee osteoarthritis
  • Both male and female
  • Individuals who able to understand simple command
  • Individuals who are willing to participate

Exclusion criteria

Exclusion Criteria:

  • History of hip and knee replacement surgery
  • History of knee arthroscopic surgery within 6 months
  • Any neurologic and musculoskeletal condition which affect their movement or balance
  • Comorbidities such as cancer or cardiovascular disease
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Other
    Test-retest reliability testing

    Minimum 50 IKOA will be evaluated with the scale on two occasions within two weeks to establish test retest reliability.

    Other: Test-retest reliability testing

Interventions

  • OtherTest-retest reliability testing

    Set of patient reported outcome measures

06

What researchers measure

Primary outcomes

  1. Change in Comprehensive Knee Osteoarthritis Index

    Set of patient reported outcome measures

    Time frame: two occasions within two weeks to establish test retest reliability

07

Study locations

1 site
  • Maharishi Markandeshwar Institute of physiotherapy and Rehabilitation
    Ambāla, Haryana 133207, India
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers. We are planned to publish the results in journal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Feb 2019, 9 months.

Of 1,126 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 9 months is below that.

Counting every sponsor, half of 1,315 studies reached it within 19 months; a quarter within 8 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2018
First posted
Apr 17, 2018
StartActual
Apr 17, 2018
Primary completionActual
Feb 12, 2019
CompletionActual
Feb 13, 2019
Last update
Mar 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03498833
Lead sponsor
Maharishi Markendeswar University (Deemed to be University)
Responsible party
Asir John Samuel (Associate Professor and Research Scholar, Maharishi Markendeswar University (Deemed to be University)) — Principal investigator
First posted
Apr 17, 2018
Start date
Apr 17, 2018
Primary completion
Feb 12, 2019
Completion
Feb 13, 2019
Last update
Mar 7, 2019

Study contacts

Kanimozhi D Narkeesh, PhD
study director · Maharishi Markandeshwar Institute of physiotherapy and Rehabilitation

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion